HMI-103 / Homology Medicines - LARVOL DELTA

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: Homology Medicines, Inc | Trial completion date: Jun 2028 ➔ Sep 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jun 2026 ➔ Sep 2023; Homology Medicines Inc. has discontinued the development of this program.

Trial completion date • Trial primary completion date • Trial termination • Metabolic Disorders • Phenylketonuria • Rare Diseases

Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Homology Medicines, Inc | Recruiting ➔ Active, not recruiting

Enrollment closed • Metabolic Disorders • Phenylketonuria • Rare Diseases

Safety and Efficacy of HMI-103, a Gene Editing Development Candidate in Adults With Classical PKU Due to PAH Deficiency (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Homology Medicines, Inc | Not yet recruiting ➔ Recruiting | Trial completion date: May 2029 ➔ Jun 2028 | Initiation date: Mar 2022 ➔ Jun 2022 | Trial primary completion date: May 2024 ➔ Jun 2026

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Metabolic Disorders • Phenylketonuria • Rare Diseases